A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic InterventionRoland Rad, Allan Bradley, Maren Hieber et al.|Cancer Cell|2013Cited by 216
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumabMasahito Kotaka, Tae Won Kim, Rui‐Hua Xu et al.|癌症：英文版|2016Cited by 15
Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trialFeng‐Hua Wang, Rui‐Hua Xu, Guanghai Dai et al.|Chinese Journal of Cancer Research|2021Cited by 11
Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial.Jin Li, Wei Wang, Shukui Qin et al.|Journal of Clinical Oncology|2019Cited by 6